首页|期刊导航|中国病理生理杂志|S100A10在三阴性乳腺癌中的促癌机制研究

S100A10在三阴性乳腺癌中的促癌机制研究OA

Tumor-promoting role of S100A10 in triple-negative breast cancer

中文摘要英文摘要

目的:探讨S100钙结合蛋白A10(S100 calcium-binding protein A10,S100A10)对三阴性乳腺癌(tri-ple-negative breast cancer,TNBC)细胞活力、迁移、集落形成、凋亡、周期和体内肿瘤生长的影响及其作用机制.方法:选用TNBC细胞系SUM-159PT和MDA-MB-231进行体外功能实验,通过慢病毒介导构建S100A10敲减和过表达细胞模型,采用CCK-8、集落形成、划痕实验、Transwell实验及流式细胞术分别检测细胞活力、迁移、细胞周期及凋亡情况;Western blot分析凋亡通路蛋白Bax和Bcl-2的表达状况.将经慢病毒转染构建的稳定敲减S100A10的MDA-MB-231细胞皮下接种于NCG小鼠,以观察S100A10对TNBC肿瘤形成能力的影响.基于RNA测序分析S100A10敲减后MDA-MB-231细胞中差异基因的通路富集情况,并采用Western blot验证NF-κB信号通路相关蛋白的表达;进一步采用双萤光素酶报告基因实验验证NF-κB关键转录因子RelA对S100A10的调控作用.结果:体外实验结果显示,敲减S100A10可显著抑制TNBC细胞的活力、迁移、集落形成能力,诱导细胞周期阻滞,并上调Bax表达,下调Bcl-2表达,促进细胞凋亡(P<0.05);而过表达S100A10则呈现相反的作用(P<0.05).体内实验结果表明,敲减S100A10可显著抑制NCG小鼠皮下移植瘤的生长(P<0.05).S100A10敲减后差异表达基因显著富集于NF-κB信号通路;可显著抑制P65的磷酸化水平,而过表达S100A10则呈现相反的作用(P<0.05).RelA可增强S100A10启动子活性(P<0.05),提示NF-κB信号通路可能存在转录水平调控S100A10的表达.结论:在TNBC,S100A10能够促进细胞的活力和迁移,抑制细胞凋亡并促进小鼠体内肿瘤生长,可能与S100A10/NF-κB环路有关.

AIM:To investigate the effects of S100 calcium-binding protein A10(S100A10)on cell viability,migration,colony-forming capacity,apoptosis,cell cycle progression,and tumorigenicity of triple-negative breast cancer(TNBC)cells in vivo,as well as to explore the underlying molecular mechanisms.METHODS:The human TNBC cell lines SUM159PT and MDA-MB-231 were employed for functional characterization in vitro.The stable cell models of S100A10 knockdown and overexpression were established via lentiviral transduction and subsequent antibiotic selection in these cells.Cell viability was quantified by the CCK-8 assay,clonogenic potential was evaluated by colony formation as-say,migratory capacity was assessed via wound-healing and Transwell migration assays,cell cycle distribution and apopto-sis rates were determined by flow cytometry.The expression levels of apoptosis-related proteins,including pro-apoptotic Bax and anti-apoptotic Bcl-2,were examined by Western blot.To evaluate the impact of S100A10 on TNBC tumorigenici-ty in vivo,MDA-MB-231 cells with stable S100A10 knockdown were subcutaneously injected into immunodeficient NCG mice.RNA sequencing was performed on S100A10-knockdown versus control MDA-MB-231 cells to identify differentially expressed genes and conduct pathway enrichment analysis.Western blot was conducted to verify the expression of NF-κB signaling pathway-related proteins.Finally,a dual-luciferase reporter assay was conducted to determine whether the key NF-κB transcription factor RelA directly binds to and transactivates the S100A10 promoter.RESULTS:Functional as-says in vitro revealed that S100A10 knockdown significantly suppressed viability,migration and clonogenic capacity in TN-BC cells,induced G0/G1-phase cell cycle arrest,upregulated the pro-apoptotic protein Bax,downregulated the anti-apop-totic protein Bcl-2 and increased apoptotic cell death(all P<0.05).In contrast,S100A10 overexpression consistently re-versed these phenotypes(all P<0.05).In vivo,stable S100A10 knockdown markedly suppressed the growth of subcutane-ous xenograft tumors in immunodeficient NCG mice(P<0.05).The results of RNA sequencing analysis revealed that dif-ferentially expressed genes following S100A10 knockdown were significantly enriched in the NF-κB signaling pathway.Consistent with this,Western blot analysis further demonstrated that S100A10 knockdown significantly reduced phosphory-lation of the NF-κB subunit P65,whereas S100A10 overexpression enhanced P65 phosphorylation(both P<0.05).Fur-thermore,dual-luciferase reporter assays confirmed that the NF-κB transcription factor RelA directly transactivated the S100A10 promoter,suggesting that the NF-κB signaling pathway might regulate S100A10 expression at the transcriptional level.CONCLUSION:In TNBC,S100A10 can promote cell viability,migration,inhibit cell apoptosis,and accelerate tumor growth,which may be related to the S100A10/NF-κB loop.

郭美岑;谢吉;李艳;王敏;袁静簃;杨丽;张荣华;王攀攀

暨南大学药学院,广东 广州 510632||暨南大学生物活性分子与成药性优化全国重点实验室,广东 广州 510632暨南大学药学院,广东 广州 510632||暨南大学生物活性分子与成药性优化全国重点实验室,广东 广州 510632广州中医药大学第一附属医院,广东 广州 510405暨南大学中医学院,广东 广州 510632暨南大学中医学院,广东 广州 510632暨南大学生物活性分子与成药性优化全国重点实验室,广东 广州 510632暨南大学中医学院,广东 广州 510632||暨南大学中医药与健康研究院,广东 广州 510632||广东省中医药信息化重点实验室,广东 广州 510632暨南大学生物活性分子与成药性优化全国重点实验室,广东 广州 510632||暨南大学中医药与健康研究院,广东 广州 510632||广东省中医药信息化重点实验室,广东 广州 510632||暨南大学附属第一医院,广东 广州 510632

医药卫生

三阴性乳腺癌S100钙结合蛋白A10NF-κB信号通路转录调控

triple-negative breast cancerS100 calcium-binding protein A10NF-κB signaling pathwaytranscriptional regulation

《中国病理生理杂志》 2026 (5)

863-874,12

国家自然科学基金资助项目(No.81603342)广东省基础与应用基础研究基金资助项目(No.2024A1515012948No.2022A1515012641)暨南大学生物活性分子与成药性优化全国重点实验室竞争性研究项目(No.SKLBMDA-FY25015)

10.3969/j.issn.1000-4718.2026.05.004

评论